18518981. Treatment of Glaucoma by Neuroprotection simplified abstract (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA)
Contents
- 1 Treatment of Glaucoma by Neuroprotection
- 1.1 Organization Name
- 1.2 Inventor(s)
- 1.3 Treatment of Glaucoma by Neuroprotection - A simplified explanation of the abstract
- 1.4 Simplified Explanation
- 1.5 Potential Applications
- 1.6 Problems Solved
- 1.7 Benefits
- 1.8 Potential Commercial Applications
- 1.9 Possible Prior Art
- 1.10 Unanswered Questions
- 1.11 Original Abstract Submitted
Treatment of Glaucoma by Neuroprotection
Organization Name
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Inventor(s)
Lingling Zhang of Berkeley CA (US)
Treatment of Glaucoma by Neuroprotection - A simplified explanation of the abstract
This abstract first appeared for US patent application 18518981 titled 'Treatment of Glaucoma by Neuroprotection
Simplified Explanation
The patent application discusses the modulation of ocular serpinA3 activity for the treatment of glaucoma through neuroprotection by administering a serpinA3 polypeptide or a nucleic acid encoding the serpinA3 polypeptide to an eye in need.
- SerpinA3 activity is modulated to treat glaucoma by neuroprotection.
- Administering a serpinA3 polypeptide or a nucleic acid encoding the serpinA3 polypeptide to an eye in need.
Potential Applications
The technology could be applied in the development of new treatments for glaucoma, a common eye disease that can lead to vision loss if left untreated.
Problems Solved
This technology addresses the need for more effective treatments for glaucoma that focus on neuroprotection to prevent vision loss.
Benefits
The use of serpinA3 polypeptide or its encoding nucleic acid could potentially provide a novel approach to treating glaucoma by targeting neuroprotection in the eye.
Potential Commercial Applications
The technology could have commercial applications in the pharmaceutical industry for the development of new glaucoma treatments.
Possible Prior Art
Prior research may have explored the role of serpinA3 in ocular health, but the specific application for treating glaucoma through neuroprotection may be novel.
Unanswered Questions
How does the serpinA3 polypeptide specifically target neuroprotection in the eye for the treatment of glaucoma?
The mechanism of action of serpinA3 in providing neuroprotection in the context of glaucoma treatment is not fully explained in the abstract.
What are the potential side effects or limitations of administering serpinA3 polypeptide for the treatment of glaucoma?
The abstract does not mention any potential drawbacks or limitations of using serpinA3 for glaucoma treatment, which could be important considerations in further development and application of this technology.
Original Abstract Submitted
Ocular serpinA3 activity is modulated to treat glaucoma by neuroprotection, comprising administering to an eye in need thereof a serpinA3 polypeptide or a nucleic acid encoding the serpinA3 polypeptide.
